Syndax is employing epigenetics—a novel way to control gene regulation—to overcome the problem of resistance seen with oncology treatments.
Syndax is a late-stage oncology company supported by top venture capitalists
and led by industry experts
developing treatments for large markets including metastatic breast
cancer. The Company’s platform is based on employing epigenetics to overcome the problem of resistance in oncology care. Syndax holds worldwide rights to entinostat
, an oral, highly selective histone deacetylase (HDAC) inhibitor, which inhibits cancer-relevant HDAC enzymes which contribute to epigenetic alterations driving cancer growth and drug tolerance. Entinostat’s unique pharmacokinetic properties, convenient oral dosing and HDAC selectivity, maximize the opportunity to safely combine with and potentially extend the benefit of proven cancer therapies. Entinostat has demonstrated promising activity in randomized, phase 2 clinical trials
in combination with the targeted therapies.